INS and metabolic disease: Seventh, alterations in the competitive advantages in skeletal muscle-cells (e.g., decrements in insulin sensitivity) are the major driver of metabolic diseases (DeFronzo, 1988; DeFronzo et al., 1992; DeFronzo and Tripathy, 2009).